Clinical trials: Papilloma Viral Infection
Papilloma Viral Infection, CIN1
Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)
HPV infection can lead to cancer, especially when precancerous lesions have developed and high-risk HPV is present. Glizigen is an oral and intravaginal treatment based on activated glycyrrhizinic acid that has shown potential…
- Conditions
- Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion
- Trial name
- NCT05916911
- Testing
- Glizigen
- Where
- 4 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Catalysis SL
Human Papilloma Virus Infection
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.
- Trial name
- NCT01567813
- Volunteers
- 114,035 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papilloma Viral Infection, Papillomavirus Infections
Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal
A randomized, double-blind, phase II clinical trial was conducted versus placebo in 110 patients with esophageal human papillomavirus.
- Conditions
- Papilloma Viral Infection, Papillomavirus Infections, Esophageal Viral Wart, Esophageal Verrucous Carcinoma
- Trial name
- NCT03584308
- Testing
- Viusid®, Glizigen®
- Where
- Cuba
- Volunteers
- 110 people
- Sponsor
- Catalysis SL
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Genital Infection Viral, HUMAN PAPILLOMA VIRUS
Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL
Human Papillomavirus (HPV) 16 and HPV 18 (the two virus genotypes targeted by the ProCervix vaccine) are the most common HPV genotypes associated with at least 70% of squamous cell carcinomas and 82% of adenocarcinomas of the…
- Trial name
- RHEIA-VAC (NCT01957878)
- Testing
- ProCervix
- Where
- 40 sites in Belgium, Finland and 5 more
- Volunteers
- 239 people
- Sponsor
- Genticel